Mereo BioPharma Group plc
MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Naviā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.80
Price+2.27%
$0.04
1Y
Price
Market Cap
$284.577m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-2858.8%
EBITDA Margin-2923.2%
Net Profit Margin-1530.2%
Free Cash Flow MarginRevenue
$1.564m
-
1y CAGR+154.5%
3y CAGR+91.9%
5y CAGREarnings
-$49.550m
-14.6%
1y CAGR-15.8%
3y CAGR-104.1%
5y CAGREPS
-$0.32
-10.3%
1y CAGR+42.3%
3y CAGR-51.7%
5y CAGRBook Value
$54.177m
$62.631m
Assets$8.454m
Liabilities$601k
DebtDebt to Assets
1.0%
-
Debt to EBITDAFree Cash Flow
-$32.939m
+1.8%
1y CAGR-3.1%
3y CAGR-145.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company